IHIlse Ea Hoffman

Ilse Ea Hoffman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilse Ea Hoffman has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • E M Veys

    Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

    1 shared publication
  • Eric M Veys

    Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, Ghent 9000, Belgium

    1 shared publication
  • F De Keyser

    Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

    1 shared publication
  • Filip De Keyser

    Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, Ghent 9000, Belgium

    1 shared publication
  • H Mielants

    Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

    1 shared publication
  • Isabelle Peene

    Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, Ghent 9000, Belgium

    1 shared publication

Latest Publications

  • Open Access

    Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy

    by I E A Hoffman, P Demetter, M Peeters, M De Vos, H Mielants, E M Veys, F De Keyser

    Objectives: To investigate whether anti-Saccharomyces cerevisiae antibodies (ASCA), a marker for Crohn’s disease (CD), are present in spondyloarthropathies (SpA) and in the subgroups ankylosing spondylitis (AS), undifferentiated SpA (uSpA), and psoriatic arthritis (PsA), in comparison with healthy and inflammatory controls (patients with rheumatoid arthritis (RA)). Methods: ASCA IgA and IgG levels were measured with an enzyme linked immunosorbent assay (ELISA) kit (Medipan, Germany) in 26 patients with CD, 108 patients with SpA (43 patients with AS, 20 patients with uSpA, 45 patients with PsA), 56 patients with RA and 45 healthy controls. Gut biopsy samples were available in 18 AS and 10 patients with uSpA, these samples were screened for the presence of inflammation. Results: Both ASCA IgG and IgA levels were raised in CD compared with healthy controls and patients with RA. ASCA IgA, but not IgG levels, were higher in SpA than in both healthy and RA controls. ASCA IgA levels were raised in AS and uSpA, but not in PsA. No significant differences in ASCA IgA levels were noted between patients with SpA with and without histological gut inflammation. Conclusion: ASCA IgA levels are significantly higher in SpA, and more specifically in AS, than in healthy controls and patients with RA. This is the first serum marker associated with SpA. No correlation between the presence of subclinical bowel inflammation and ASCA IgA levels was noted. However, it remains to be evaluated whether patients with SpA with ASCA have an increased risk of developing CD.


  • Open Access

    Detection of Specific Antinuclear Reactivities in Patients with Negative Anti-nuclear Antibody Immunofluorescence Screening Tests

    by Ilse Ea Hoffman, Isabelle Peene, Eric M Veys, Filip De Keyser

    Background: For detection of anti-nuclear antibodies (ANAs) and antibodies to extractable nuclear antigens (ENAs), samples frequently are screened with indirect immunofluorescence (IIF); further determination of anti-ENA antibodies is performed only when the result is positive. However, because anti-ENA reactivities are found in samples with low fluorescence intensities, we determined anti-ENA antibodies in samples with negative IIF and thus calculated the sensitivity of IIF for specific ANAs. Methods: We collected 494 samples consecutively referred by rheumatologists for routine ANA testing. IIF on HEp-2 and HEp-2000 (HEp-2 cells transfected with Ro60 cDNA) and line immunoassay (LIA) for the detection of specific ANAs were performed on all samples. Results: Fluorescence intensities and patterns on HEp-2 were strongly correlated with those on HEp-2000 [Spearman ρ = 0.852 (P P Conclusion: The HEp-2 and HEp-2000 substrates perform comparably for fluorescence intensities and patterns and for detecting specific ANAs, but some patients with negative IIF show reactivity on LIA. We recommend testing for fine reactivities, regardless of the IIF result, when the clinical suspicion for rheumatic connective tissue disease is high.